CytoMed Therapeutics Announces China Research Collaboration To Enhance Its Allogeneic CAR γδ T In Vivo Persistency; The MOU Signed By Cytomed And Hangzhou CNK Therapeutics Co., Ltd Is The First Of Several Collaborative Efforts In North Asia
Portfolio Pulse from Happy Mohamed
CytoMed Therapeutics Limited (NASDAQ:GDTC) has signed a Memorandum of Understanding (MOU) with Hangzhou CNK Therapeutics Co., Ltd. This collaboration will allow CytoMed to use CNK's PiggyBac technology to enhance the persistency of its CAR γδ T cells in cancer treatment. The MOU lasts for one year, with the option to renew, and could potentially lead to a joint venture for clinical trials in China.
August 15, 2023 | 5:03 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
CytoMed's partnership with CNK Therapeutics could enhance the effectiveness of its CAR γδ T cell cancer treatment, potentially leading to increased demand and revenue. The possibility of joint clinical trials in China also opens up a new market for the company.
The partnership with CNK Therapeutics allows CytoMed to enhance its CAR γδ T cell technology, potentially increasing its effectiveness in cancer treatment. This could lead to increased demand for the treatment, boosting CytoMed's revenue. Additionally, the potential for joint clinical trials in China opens up a new market for CytoMed, which could further increase its revenue and stock value.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 100